Nothing Special   »   [go: up one dir, main page]

SG10201702048VA - Apixaban liquid formulations - Google Patents

Apixaban liquid formulations

Info

Publication number
SG10201702048VA
SG10201702048VA SG10201702048VA SG10201702048VA SG10201702048VA SG 10201702048V A SG10201702048V A SG 10201702048VA SG 10201702048V A SG10201702048V A SG 10201702048VA SG 10201702048V A SG10201702048V A SG 10201702048VA SG 10201702048V A SG10201702048V A SG 10201702048VA
Authority
SG
Singapore
Prior art keywords
liquid formulations
apixaban liquid
apixaban
formulations
liquid
Prior art date
Application number
SG10201702048VA
Inventor
Sherif Ibrahim Farag Badawy
Susan Lum
Original Assignee
Bristol Myers Squibb Holdings Ireland
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Holdings Ireland, Pfizer filed Critical Bristol Myers Squibb Holdings Ireland
Publication of SG10201702048VA publication Critical patent/SG10201702048VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201702048VA 2012-09-26 2013-09-26 Apixaban liquid formulations SG10201702048VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705943P 2012-09-26 2012-09-26
US201361773032P 2013-03-05 2013-03-05

Publications (1)

Publication Number Publication Date
SG10201702048VA true SG10201702048VA (en) 2017-04-27

Family

ID=49447800

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201702048VA SG10201702048VA (en) 2012-09-26 2013-09-26 Apixaban liquid formulations
SG11201501743UA SG11201501743UA (en) 2012-09-26 2013-09-26 Apixaban liquid formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201501743UA SG11201501743UA (en) 2012-09-26 2013-09-26 Apixaban liquid formulations

Country Status (18)

Country Link
US (2) US9452134B2 (en)
EP (1) EP2900217A1 (en)
JP (1) JP6248112B2 (en)
KR (1) KR102035373B1 (en)
CN (1) CN104736142B (en)
AU (1) AU2013323435C1 (en)
BR (1) BR112015005995A2 (en)
CA (1) CA2885899A1 (en)
HK (1) HK1212900A1 (en)
IL (1) IL237804A0 (en)
IN (1) IN2015DN01902A (en)
MX (1) MX358097B (en)
MY (1) MY179191A (en)
NZ (1) NZ630763A (en)
PH (1) PH12015500590B1 (en)
RU (1) RU2660358C2 (en)
SG (2) SG10201702048VA (en)
WO (1) WO2014052678A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
DK3781132T3 (en) * 2018-04-16 2024-04-22 Bristol Myers Squibb Co APIXABAN FORMULATIONS
EP3838265A4 (en) 2018-08-14 2022-05-11 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition and preparation method therefor
BR112022008551A2 (en) 2019-11-13 2022-08-09 Unison Pharmaceuticals Pvt Ltd PHARMACEUTICAL DOSAGE FORM OF ORAL DISASSEMBLY AND, PROCESS FOR THE PREPARATION OF AN ORAL DISASSEMBLY DOSAGE FORM
CA3202161A1 (en) 2020-12-13 2022-06-16 Matthaios VIDALIS Liquid apixaban formulation in small dose volume
CN113384526A (en) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 Stable apixaban oral solution preparation and preparation method thereof
US12214075B2 (en) 2021-10-27 2025-02-04 Pharma-Data Research And Development Single Member S.A. Apixaban suspension and preparation method
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
US12194028B2 (en) 2022-03-09 2025-01-14 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
WO2023218482A1 (en) * 2022-05-09 2023-11-16 Syri Research Private Limited Liquid oral formulation of apixaban or pharmaceutically acceptable salt thereof
US12213972B2 (en) * 2022-07-27 2025-02-04 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
WO2024160789A1 (en) 2023-01-30 2024-08-08 Tap Pharmaceuticals Ag Liquid pharmaceutical formulations of apixaban
US11833138B1 (en) 2023-01-30 2023-12-05 Tap Pharmaceuticals Ag Liquid pharmaceutical formulations of apixaban
EP4450064A1 (en) 2023-04-14 2024-10-23 Novick BioSciences Private Limited Apixaban compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
ME00090B (en) * 2001-09-21 2010-10-10 Bristol Myers Squibb Holdings Ireland Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
MX2007010163A (en) * 2005-02-25 2008-02-22 Biomarin Pharm Inc Room temperature stable aqueous liquid pharmaceutical composition.
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
EP2242476A2 (en) * 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
KR101991367B1 (en) * 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
SMT202000093T1 (en) * 2009-06-16 2020-03-13 Pfizer Dosage forms of apixaban
PT2538925E (en) 2010-02-25 2016-03-18 Pfizer Apixaban formulations
EP2484775A1 (en) 2011-02-07 2012-08-08 Siemens Healthcare Diagnostics Products GmbH Heparin-insensitive method for detecting direct clotting factor inhibitors
RU2638155C1 (en) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Benzo[d]isoxazole derivatives and their application

Also Published As

Publication number Publication date
CN104736142B (en) 2020-03-03
JP6248112B2 (en) 2017-12-13
AU2013323435C1 (en) 2018-04-12
KR102035373B1 (en) 2019-10-22
RU2660358C2 (en) 2018-07-05
MX2015003393A (en) 2015-09-25
JP2015531377A (en) 2015-11-02
HK1212900A1 (en) 2016-06-24
NZ630763A (en) 2017-01-27
EP2900217A1 (en) 2015-08-05
PH12015500590B1 (en) 2019-08-23
US20160263097A1 (en) 2016-09-15
AU2013323435A8 (en) 2015-04-23
CN104736142A (en) 2015-06-24
US10016362B2 (en) 2018-07-10
KR20150058243A (en) 2015-05-28
BR112015005995A2 (en) 2017-07-04
RU2015115127A (en) 2016-11-20
WO2014052678A1 (en) 2014-04-03
MY179191A (en) 2020-10-30
US9452134B2 (en) 2016-09-27
SG11201501743UA (en) 2015-04-29
PH12015500590A1 (en) 2015-05-25
AU2013323435B2 (en) 2017-10-19
IN2015DN01902A (en) 2015-08-07
IL237804A0 (en) 2015-05-31
CA2885899A1 (en) 2014-04-03
MX358097B (en) 2018-08-06
US20150224053A1 (en) 2015-08-13
AU2013323435A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
HK1212900A1 (en) Apixaban liquid formulations
HK1208372A1 (en) Liquid formulation
TWI563077B (en) Cleaning formulations
HK1203812A1 (en) Novel pharmaceutical formulations
SI2877155T1 (en) Opioid formulations
HK1204973A1 (en) Diclofenac formulations
SG11201407759SA (en) Liquid distribution device
HK1201739A1 (en) Liquid cosmetic
HK1202445A1 (en) New formulation
IL289157A (en) Opioid formulations
HK1205146A1 (en) Pharmaceutical formulation
ZA201306000B (en) Stable formulation
GB201302688D0 (en) Detergent formulation
PL2908835T3 (en) Stable formulations
EP2772141A4 (en) Liquid sweetener composition
EP2830607A4 (en) Polyvinylpyrrolidone-containing acetaminophen liquid formulations
HK1209339A1 (en) Pharmaceutical formulations
HK1204945A1 (en) Pharmaceutical formulation containing flupirtin
GB201206178D0 (en) Formulations
GB201211247D0 (en) Improved formulation
GB201211403D0 (en) Pharmaceutical formulations
GB201211406D0 (en) Pharmaceutical formulations